DUSP16 and neoplasm: DUSP16 expression was determined by immunohistochemistry (Fig. 7C), with the disease-free survival (DFS)—defined as the interval between the completion of chemoradiation to the first histologically or radiologically confirmed tumor recurrence locally in the head and neck region or distant metastases—was defined in 50 patients.